EQS-News : Relief Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding AG

 
 EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): AGMEGM 
Relief Announces Notice of Extraordinary General Meeting of RELIEF 
THERAPEUTICS Holding AG 
 
2020-11-23 / 07:00 
 
*Relief Announces Notice of Extraordinary General Meeting of * 
*RELIEF THERAPEUTICS Holding AG* 
 
*Geneva, Switzerland, November 23, 2020 -* RELIEF THERAPEUTICS Holding AG 
(SIX: RLF, OTCQB: RLFTF) ("*Relief*" or the "*Company*"), a 
biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in 
advanced clinical development to treat severe COVID-19 patients, today gives 
notice of an Extraordinary General Meeting (EGM) of shareholders to be held 
on December 17, 2020. 
 
As a result of the exceptional circumstances due to the coronavirus 
pandemic, the EGM will be held without the physical presence of 
shareholders, representatives and third parties in accordance with the 
requirements of the Ordinance of the Swiss Federal Council regarding 
measures on combatting the coronavirus. Shareholders are able to exercise 
their voting rights through giving all voting instructions to the 
independent proxy, Mr. Thomas Hua. Guidelines on how to deliver voting 
instructions can be found in the EGM formal invitation, which will be sent 
out within the next few days to registered shareholders. Instructions 
transmitted electronically should be executed no later than December 14, 
2020, 23:59 (CET). 
 
*Entitlement to vote * 
 
Those shareholders who are registered in the share register as of December 
4, 2020, 13:00 (CET), are entitled to vote. No registration in the share 
register will be made from December 4 through December 17, 2020. 
Shareholders who sell all or part of their shares prior to the General 
Meeting will no longer be entitled to vote to that extent. 
 
*Agenda items:* 
 
1. Election of the Chair of the Extraordinary General Meeting 
 
2. Election of Tom Plitz as new member of the Board of Directors 
 
3. Votes on the compensation of the members of the Board of Directors and of 
the Executive Committee 
 
4. Increase of authorized share capital 
 
5. Increase of conditional share capital 3b2 
 
The full agenda is available for download on the Company's website 
(https://relieftherapeutics.com/investor-relations [1]). 
 
*Election of Tom Plitz as new member of the Board of Directors* 
 
Tom is Chief Executive Officer of Chord Therapeutics SA, a privately held 
biopharmaceutical firm based in Geneva, Switzerland. He has more than two 
decades of experience in pharmaceutical R&D, most recently as Chief 
Scientific Officer of the rare disease company Wilson Therapeutics. Wilson 
Therapeutics was acquired for USD 855 million by Alexion Pharmaceuticals in 
April 2018. Tom's previous assignments include senior roles at Serono, 
Merck, and Shire, where he worked across multiple therapeutic areas, 
including neuroinflammatory, metabolic, and rare diseases. Tom holds a Ph.D. 
from Technical University of Munich, Germany. 
 
*Votes on the compensation of the members of the Board of Directors and of 
the Executive Committee* 
 
The Board of Directors recommends adjusting the compensation pool available 
for the remuneration of its members in the ongoing financial year from CHF 
1,000,000 (as previously accepted by July's AGM) to CHF 1,500,000. 
Furthermore, with the rapid development of the Company and its activities 
over the last months, the Board of Directors has reinforced, and will 
continue to reinforce, the Relief management team. Therefore, a request is 
made for the approval of a compensation pool of CHF 5,000,000 for management 
remuneration for the financial year 2021. 
 
*Increase of authorized capital and of conditional share capital 3b2* 
 
The authorized share capital is intended for the future financing of the 
Company, as required in connection with future projects as well as for 
responding quickly to strategic business opportunities. An increase from 
1,056,726,052 shares to 1,250,000,000 shares will provide the Company 
additional flexibility to raise capital or pursue acquisitions. 
 
An increase of the conditional share capital from 740,329,636 shares to 
960,000,000 shares will provide additional flexibility should the Company 
need to use financing instruments with conversion features. This measure is 
being put in place as a precaution and to ensure adequate funds to complete 
all study plans for RLF-100TM. As further explained in the EGM invitation, 
the resulting available number of conditional shares will be 340,000,000 
shares as recent issuances of 620,000,000 new shares out of the conditional 
share capital 3b2 are not yet reflected in the Articles of Association. 
 
*###* 
 
*ABOUT RELIEF* 
Relief focuses primarily on clinical-stage programs based on molecules of 
natural origin (peptides and proteins) with a history of clinical testing 
and use in human patients or a strong scientific rationale. Currently, 
Relief is concentrating its efforts on developing new treatments for 
respiratory disease indications. Its lead drug candidate RLF-100TM 
(aviptadil), synthetic vasoactive intestinal peptide (VIP), is being 
investigated in two placebo-controlled U.S. Phase 2b/3 clinical trials in 
respiratory deficiency due to COVID-19. RLF-100TM is believed to be the 
first COVID-19 therapeutic to demonstrate the ability to block replication 
of the SARS-CoV-2 virus in human lung cells and monocytes, while also 
preventing synthesis of cytokines in the lung. Since July 2020, severe 
COVID-19 patients have been treated with RLF-100TM under U.S. FDA Emergency 
Use Investigational New Drug (IND) authorization and Expanded Access 
Protocol authorization for the treatment of respiratory failure in COVID-19. 
 
Relief also holds a patent issued in the United States and various other 
countries covering potential formulations of RLF-100TM. 
 
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the 
symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. 
 
Follow us on *LinkedIn [2]* 
 
*CONTACT                           *FOR MEDIA/INVESTOR 
RELIEF THERAPEUTICS Holding AG*    INQUIRES: 
Raghuram (Ram) Selvaraju, Ph.D.,   MC Services AG* 
MBA                                Anne Hennecke / Brittney 
Chairman of the Board              Sojeva 
Mail:                              Mail: [e-mail] 
[e-mail]     [3] 
www.relieftherapeutics.com         Tel.: [phone] 
 
Disclaimer : This communication expressly or implicitly contains certain 
forward-looking statements concerning RELIEF THERAPEUTICS Holding AG and its 
business. Such statements involve certain known and unknown risks, 
uncertainties and other factors, which could cause the actual results, 
financial condition, performance or achievements of RELIEF THERAPEUTICS 
Holding AG to be materially different from any future results, performance 
or achievements expressed or implied by such forward-looking statements. 
RELIEF THERAPEUTICS Holding AG is providing this communication as of this 
date and does not undertake to update any forward-looking statements 
contained herein as a result of new information, future events or otherwise. 
 
End of Media Release 
Language:    English 
Company:     RELIEF THERAPEUTICS Holdings AG 
             Avenue de Sécheron 15 
             1202 Genève 
             Switzerland 
E-mail:      [e-mail] 
Internet:    https://relieftherapeutics.com 
ISIN:        CH0100191136 
Listed:      SIX Swiss Exchange 
EQS News ID: 1149786 
 
End of News EQS Group News Service 
 
1149786 2020-11-23 
 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=b8b5f9da7c16ab769987aabd35afad21&application_id=1149786&site_id=vwd&application_name=news 
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=e30303c841a044416d184730bebe9fb7&application_id=1149786&site_id=vwd&application_name=news 
3: mailto:[e-mail] 
 

(END) Dow Jones Newswires

November 23, 2020 01:00 ET (06:00 GMT)